Pharmacokinetic Interactions Between the Fixed-Dose Combinations of Elvitegravir/Cobicistat/Tenofovir Disoproxil Fumarate/Emtricitabine and Elbasvir/Grazoprevir in Healthy Adult Participants.
Administration, Oral
Adult
Area Under Curve
Benzofurans
/ administration & dosage
Cobicistat
/ administration & dosage
Drug Administration Schedule
Drug Combinations
Drug Interactions
Emtricitabine
/ administration & dosage
Female
Healthy Volunteers
Humans
Imidazoles
/ administration & dosage
Male
Middle Aged
Quinolones
/ administration & dosage
Quinoxalines
/ administration & dosage
Tenofovir
/ administration & dosage
HIV/AIDS
clinical pharmacology
drug-drug interactions
hepatitis C
Journal
Clinical pharmacology in drug development
ISSN: 2160-7648
Titre abrégé: Clin Pharmacol Drug Dev
Pays: United States
ID NLM: 101572899
Informations de publication
Date de publication:
10 2019
10 2019
Historique:
received:
26
09
2018
accepted:
07
05
2019
pubmed:
8
6
2019
medline:
5
8
2020
entrez:
8
6
2019
Statut:
ppublish
Résumé
Treatment of individuals coinfected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) requires careful consideration of potential drug-drug interactions. The pharmacokinetic interaction of the HCV fixed-dose combination treatment of elbasvir/grazoprevir (EBR/GZR) when coadministered with the fixed-dose combination HIV treatment of elvitegravir/cobicistat/tenofovir disoproxil fumarate/emtricitabine (EVG/COB/TDF/FTC) was evaluated in 22 healthy adults. In period 1, oral doses of EVG/COB/TDF/FTC (150 mg/150 mg/300 mg/200 mg) were administered once daily for 7 days. In period 2, oral doses of EBR/GZR (50 mg/100 mg) were administered once daily for 10 days. In period 3, oral doses of EVG/COB/TDF/FTC were coadministered with EBR/GZR once daily for 10 days. The pharmacokinetics of EVG/COB/TDF/FTC were not clinically meaningfully altered by concomitant EBR/GZR administration. Geometric mean ratios (90%CIs) for area under the plasma concentration-time curve from time 0 to 24 hours (AUC
Substances chimiques
Benzofurans
0
Drug Combinations
0
Imidazoles
0
Quinolones
0
Quinoxalines
0
elbasvir-grazoprevir drug combination
0
elvitegravir
4GDQ854U53
Tenofovir
99YXE507IL
Emtricitabine
G70B4ETF4S
Cobicistat
LW2E03M5PG
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
952-961Informations de copyright
© 2019, The American College of Clinical Pharmacology.
Références
Platt L, Easterbrook P, Gower E, et al. Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis. Lancet Infect Dis. 2016;16(7):797-808.
Lo Re V III, Kallan MJ, Tate JP, et al. Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: a cohort study. Ann Intern Med. 2014;160(6):369-379.
Chen TY, Ding EL, Seage GR III, Kim AY. Meta-analysis: increased mortality associated with hepatitis C in HIV-infected persons is unrelated to HIV disease progression. Clin Infect Dis. 2009;49(10):1605-1615.
Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf Accessed July 19, 2018.
Coburn CA, Meinke PT, Chang W, et al. Discovery of MK-8742: an HCV NS5A inhibitor with broad genotype activity. ChemMedChem. 2013;8(12):1930-1940.
Harper S, McCauley JA, Rudd MT, et al. Discovery of MK-5172, a macrocyclic hepatitis c virus NS3/4a protease inhibitor. ACS Med Chem Lett. 2012;3(4):332-336.
Lahser F, Liu R, Bystol K, Xia E, Asante-Appiah E, Howe AY. A combination containing MK-5172 (HCV N53 protease inhibitor) and MK-8742 (HCV NS5A inhibitor) demonstrates high barrier to resistance in HCV replicons. Hepatology. 2012;56 (Suppl 4): Abstract 87.
Zeuzem S, Ghalib R, Reddy KR, et al. Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic HCV genotype 1, 4, or 6 infection: a randomized trial. Ann Intern Med. 2015;163(1):1-13.
Kwo P, Gane E, Peng CY, et al. Effectiveness of elbasvir and grazoprevir combination, with or without ribavirin, for treatment-experienced patients with chronic hepatitis C infection. Gastroenterology. 2017;152(1):164-175.
Rockstroh JK, Nelson M, Katlama C, et al. Efficacy and safety of grazoprevir and elbasvir in patients with hepatitis C virus and HIV coinfection (C-EDGE CO-INFECTION): a phase 3 trial. Lancet. 2015;2(8):e319-e327.
Roth D, Nelson DR, Bruchfeld A, et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet. 2015;386(10003):1537-1545.
Center for Drug Evaluation and Research. Clinical Pharmacology and Biopharmaceutical Reviews. Zepatier. May 28, 2015. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208261Orig1s000ClinPharmR.pdf Accessed September 13, 2017.
Deeks ED. Elvitegravir: a review of its use in adults with HIV-1 infection. Drugs. 2014;74(6):687-697.
Nguyen T, McNicholl I, Custodio JM, Szwarcberg J, Piontkowsky D. Drug interactions with cobicistat- or ritonavir-boosted elvitegravir. AIDS Rev. 2016;18(2):101-111.
Barcelo C, Gaspar F, Aouri M, et al. Population pharmacokinetic analysis of elvitegravir and cobicistat in HIV-1-infected individuals. J Antimicrob Chemother. 2016;71(7):1933-1942.
Neumanova Z, Cerveny L, Ceckova M, Staud F. Interactions of tenofovir and tenofovir disoproxil fumarate with drug efflux transporters ABCB1, ABCG2, and ABCC2; role in transport across the placenta. AIDS. 2014;28(1):9-17.
Weiss J, Rose J, Storch CH, et al. Modulation of human BCRP (ABCG2) activity by anti-HIV drugs. J Antimicrob Chemother. 2007;59(2):238-245.
Swedrowska M, Jamshidi S, Kumar A, Kelly C, Rahman KM, Forbes B. In silico and in vitro screening for P-glycoprotein interaction with tenofovir, darunavir, and dapivirine: an antiretroviral drug combination for topical prevention of colorectal HIV transmission. Mol Pharm. 2017;14(8):2660-2669.
Ray AS, Cihlar T, Robinson KL, et al. Mechanism of active renal tubular efflux of tenofovir. Antimicrob Agents Chemother. 2006;50(10):3297-3304.
Valade E, Treluyer JM, Bouazza N, et al. Population pharmacokinetics of emtricitabine in HIV-1-infected adult patients. Antimicrob Agents Chemother. 2014;58(4):2256-2261.
Kenward MG, Roger JH. Small sample inference for fixed effects from restricted maximum likelihood. Biometrics. 1997;53(3):983-997.
Manns MP, Vierling JM, Bacon BR, et al. The combination of MK-5172, peginterferon, and ribavirin is effective in treatment-naive patients with hepatitis C virus genotype 1 infection without cirrhosis. Gastroenterology. 2014;147(2):366-376.
Caro L, Du L, Huang S, et al. Relationship between transaminase levels and plasma pharmacokinetics following administration of MK-5172 with pegylated interferon alfa-2b and ribavirin to HCV genotype G1 treatment-naive patients. J Hepatol. 2013;58(suppl 1):S328.
Yeh W, Marshall W, Mangin E, et al. Pharmacokinetic interactions between the HCV NS5A inhibitor MK-8742 and efavirenz. Presented at: 2014 Conference on Retroviruses and Oppotunistic Infections (CROI); March 3-6, 2014; Boston, MA.
Yeh WW, Fraser IP, Caro L, et al. No meaningful PK interaction between HCV protease inhibitor MK-5172 and tenofovir or raltegravir. Presented at: 2014 Conference on Retroviruses and Opporunistic Infections (CROI); March 3-6, 2014; Boston, MA.
Feng HP, Caro L, Guo Z, et al. Coadministration of Zepatier (grazoprevir/elbasvir) with tenofovir disoproxil fumarate resulted in no clinically meaningful drug-drug interaction in healthy subjects. Rev Antiviral Ther Infect Dis. 2016;6:62-63.